Pancreatic cancer
MAPKeeper301
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer
Trial overview
Clinical Area
Medical Oncology
Disease
Pancreatic
Disease site
Gastrointestinal (GI)
Study Phase
III
Trial Identifiers
Registration number: NCT07562152
Principal Investigator(s)
··
··